Cantai Therapeutics

Operator of a therapeutics company intended to advance next-generation bispecific antibodies for autoimmune diseases. The company focuses on treating autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies, enabling patients suffering from immune-mediated and autoimmune diseases to receive effective treatments.